Emergency Medicine Doctors in Menomonie, WI Accepting Medicare

7 Emergency Medicine doctors found. Showing 1 - 7

Albert Ke-chung Hsiao, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2321 Stout Rd, Menomonie, WI 54751 Phone: 702-528-0847

Dr. Jeffrey Eaton Ilsley, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2321 Stout Rd, Menomonie, WI 54751 Phone: 715-235-5531

Adam Hallet, LAT Emergency Medicine - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 2321 Stout Rd, Menomonie, WI 54751 Phone: 715-619-0909

Marek Kaminski, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2321 Stout Rd, Menomonie, WI 54751 Phone: 715-235-5531    Fax: 715-233-7485

Lance W. Weagant, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2321 Stout Rd, Menomonie, WI 54751 Phone: 715-235-9671

Shawn W Swaenepoel, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2321 Stout Rd, Menomonie, WI 54751 Phone: 715-235-5531    Fax: 715-233-7645

Matthew Joseph Borgo, M.D. Emergency Medicine - Hospice and Palliative Medicine Medicare: Accepting Medicare Assignments Practice Location: 2321 Stout Rd, Menomonie, WI 54751 Phone: 715-235-9671

News Archive

Study shows that divorced people are more likely to die from preventable accidents than married counterparts

Divorced people are more likely to die from preventable accidents than married counterparts, according to a new study from sociologists at Rice University and the University of Pennsylvania.

Study to examine early, inherited form of Alzheimer's disease

The adult children of people diagnosed with inherited Alzheimer's disease are the focus of a new study to better understand the biology of the disease.

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

U.S. preparedness for drug-resistant TB strains questioned

Multidrug-resistant TB is at epidemic proportions in some parts of the world - a growing problem the U.S. is surprisingly unprepared for. The U.S. beat back multidrug-resistant tuberculosis in the 1990s.

Read more Medical News

› Verified 6 days ago